In a phase 3 randomized trial, investigators evaluated whether finerenone added to the background renin–angiotensin system blockade, thereby reducing albuminuria in adults with type 1 diabetes and chronic...
A nationwide target trial emulation in US veterans with type 2 diabetes found that semaglutide initiation was associated with a twofold increased risk of nonarteritic anterior ischemic optic neuropathy...
A multicenter trial conducted in China found that an artificial intelligence–based insulin clinical decision support system provided glycemic outcomes comparable to standard therapy administered by senior...
As the clinical use of GLP-1 receptor agonists (RA) expands beyond diabetes and obesity, clinicians must balance emerging cardiometabolic and organ-specific benefits with the challenges of persistent...
A randomized clinical trial found no significant difference in breast development between cyproterone acetate and spironolactone in transgender individuals undergoing feminizing hormone therapy. However,...
In the phase 3 QWINT-1 trial, efsitora achieved noninferior reductions in glycated hemoglobin compared with once-daily insulin glargine over 52 weeks, with similar fasting glucose outcomes.
Anuradha Krishnan, BA, research analyst at dQ&A, previews her presentation at the 2025 American Diabetes Association Scientific Sessions, sharing findings from a multi-country survey examining how...
